---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-26-002020"
form_type: "8-K"
ticker: "NTHI"
cik: "0001979414"
company_name: "NEONC TECHNOLOGIES HOLDINGS, INC."
filed_at: "2026-03-06T23:59:59+00:00"
generated_at: "2026-05-15T19:02:35.391721+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# NeOnc reports Phase 1 dose-escalation results for NEO212; RP2D set at 610 mg

## Summary
- MTD reached at 810 mg (Cohort 5) with second DLT; dose escalation halted.
- Recommended Phase 2 Dose (RP2D) set at 610 mg; Phase 2a metastasis start at 400 mg.
- Early efficacy signals: partial response in recurrent GBM (~60% tumor reduction after 21 cycles) and stable disease in brain metastasis.
- No clinically meaningful myelosuppression; 39x lower AIC vs TMZ indicating lower toxicity.
- Type B FDA meeting to be requested for accelerated approval pathway.

## SEC filing metadata
- accession: 0001829126-26-002020
- form_type: 8-K
- ticker: NTHI
- cik: 0001979414
- company_name: NEONC TECHNOLOGIES HOLDINGS, INC.
- filed_at: 2026-03-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1979414/000182912626002020/0001829126-26-002020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1979414/000182912626002020/neonctechnologies_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-26-002020
- JSON: https://secwatch.observer/filing/0001829126-26-002020.json
- Plain text: https://secwatch.observer/filing/0001829126-26-002020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.